Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Drug Investigation
Published in: Clinical Drug Investigation 3/2004

01-03-2004 | Review Article

Depression during Pregnancy

Overview of Clinical Factors

Authors: Ms Heather A. Bennett, Adrienne Einarson, Anna Taddio, Gideon Koren, Thomas R. Einarson

Published in: Clinical Drug Investigation | Issue 3/2004

Login to get access

Abstract

Depression during pregnancy is common, affecting an estimated 20% of women. However, conflicting data exist concerning the outcomes of this disorder. Thus, we reviewed studies that presented evidence for the use of antidepressants and those that examined untreated depression during the gestational period, in terms of clinical and epidemiological aspects.
Observational studies have provided reassuring evidence of the safety of antidepressant use during pregnancy. However, due to the reluctance of healthcare providers to prescribe and patients to take medication during the obstetric period, approximately three-quarters of those diagnosed with depression remain untreated. Furthermore, healthcare providers apparently do not recognise the disorder in up to 50% of pregnant women who experience depression. Increased antidepressant dosing during pregnancy may be required to maintain euthymia; however, guidelines for effective dosing levels are absent. Consequently, many patients remain inadequately treated. Substantial maternal and fetal morbidity including substance abuse, functional impairment, increased risk of postnatal depression, and poor pregnancy outcomes have resulted from untreated depression.
The consequences of those outcomes are likely to be associated with substantial clinical, social and economic burdens. An incidence-based assessment of the consequences of prenatal depression would be useful in order to: (i) establish the impact on the quality of life of these patients and their families; (ii) assess the associated economic burden on individual families and the healthcare system; and (iii) to provide epidemiological data to enable the provision of suitable management strategies for these patients.
Literature
1.
Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998; 55: 694–700PubMedCrossRef
2.
Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: global burden of disease study. Lancet 1997; 349: 1498–504PubMedCrossRef
3.
Commonwealth Department of Health and Aged Care, Australian Institute of Health and Welfare. National health priority areas report. Mental health 1998. Canberra: AIHW; 1999 AIHW Cat. No. PHE 13
4.
Liu S, Prince M, Blizard B, et al. The prevalence of psychiatric morbidity and its associated factors in general health care in Taiwan. Psychol Med 2002; 32: 629–37PubMedCrossRef
5.
Statistics Canada. Health indicators, Volume 2002, No. 1, Depression. Ottawa (ON): Statistics Canada, Canadian Institute for Health Information, 2002; Catalogue No: 82-221-XIE
6.
Araya R, Rojas G, Fritsch R, et al. Common mental disorders in Santiago, Chile: prevalence and sociodemographic correlates. Br J Psychiatry 2001; 178: 228–33PubMedCrossRef
7.
8.
Lepine JP, Gastpar M, Mendlewicz J, et al. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997; 12: 19–29PubMedCrossRef
9.
Berardi D, Leggieri G, Bertti CG, et al. Depression in primary care: a nationwide epidemiological survey. Fam Pract 2002; 19: 397–400PubMedCrossRef
10.
Weissman MM, Olfson M. Depression in women: implications for health care research. Science 1995; 269: 799–806PubMedCrossRef
11.
Johanson R, Chapman G, Murray D, et al. The North Staffordshire Maternity Hospital prospective study of pregnancy-associated depression. J Psychosom Obstet Gynaecol 2000; 21: 93–7PubMedCrossRef
12.
Gotlib IH, Whiffen VE, Mount JH, et al. Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. J Consult Clin Psychol 1989; 57: 269–74PubMedCrossRef
13.
O’Hara MW. Social support, life events, and depression during pregnancy and the puerperium. Arch Gen Psychiatry 1986; 43: 569–73PubMedCrossRef
14.
Evans J, Heron J, Francomb H, et al. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001; 323: 257–60PubMedCrossRef
15.
Kelly RH, Russo J, Katon W. Somatic complaints among pregnant women cared for in obstetrics: normal pregnancy or depressive and anxiety symptom amplification revisited? Gen Hosp Psychiatry 2001; 23: 107–13PubMedCrossRef
16.
Dayan J, Creveuil C, Herlicoviez M, et al. Role of anxiety and depression in the onset of spontaneous preterm labour. Am J Epidemiol 2002; 155: 293–301PubMedCrossRef
17.
Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001; 158: 1728–30PubMedCrossRef
18.
Da Costa D Larouche J, Dritsa M, et al. Psychosocial correlate of prepartum and postpartum depressed mood. J Affect Disord 2000; 59: 31–40PubMedCrossRef
19.
McKee MD, Cunningham D, Jankowksi KR, et al. Health-related functional status in pregnancy: relationship to depression and social support in a multi-ethnic population. Obstet Gynecol 2001; 97: 988–93PubMedCrossRef
20.
Hobfoll SE, Ritter C, Lavin J, et al. Depression prevalence and incidence among inner-city pregnant and postpartum women. J Consult Clin Psychol 1995; 63: 445–53PubMedCrossRef
21.
Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome: review of the literature and preliminary findings. Epidemiol Rev 1995; 17: 165–71PubMed
22.
Chokka P. Postpartum depression: part 1. Can J CME 2002; 14: 37–48
23.
Pole M, Einarson A, Pairaudeau N, et al. Drug labeling and risk perceptions of teratogenicity: a survey of pregnant Canadian women and their health professionals. J Clin Pharmacol 2000; 40: 573–7PubMedCrossRef
24.
Stuart S, O’Hara MW, Blehar MC. Mental disorders associated with childbearing: report of the biennial meeting of the Marce Society. Psychopharmacol Bull 1998; 34: 333–8PubMed
25.
Marcus SM, Barry KL, Flynn HA, et al. Treatment guidelines for depression in pregnancy. Int J Gynecol Obstet 2001; 72: 61–70CrossRef
26.
Wisner KL, Zarin D, Holmboe ES, et al. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 2000; 157: 1933–40PubMedCrossRef
27.
Stewart DE. Antidepressant drugs during pregnancy and lactation. Int Clin Psychopharmacol 2000; 15: S19–24PubMedCrossRef
28.
Abel K. Psychiatric illness and its management in pregnancy and the puerperium. Contemp Clin Gynecol Obstet 2002; 2: 59–71
29.
Nonacs R, Cohen LS. Depression during pregnancy: diagnosis and treatment options. J Clin Psychiatry 2002; 63: 24–30PubMed
30.
Ward RK, Zamorski MA. Benefits and risks of psychiatric medications during pregnancy. Am Fam Physician 2003; 66: 629–36
31.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: merican Psychiatric Association, 1994
32.
Johnston TG, Kelly CB, Stevenson MR, et al. Plasma norepinephrine and prediction of outcome in major depressive disorder. Biol Psychiatry 1999; 46: 1253–8PubMedCrossRef
33.
A research agenda for DSM-V. Washington, DC: American Psychiatric Association, 2002
34.
First MB, Spitzer RL, Williams JB, et al. Structured clinical interview for DSM-IV (SCID-I) (User’s Guide and Interview) Research Version. New York: New York Psychiatric Institute, 2003
35.
Boyd RC, Pearson JL, Blehar MC. Prevention and treatment of depression in pregnancy and the postpartum period: summary of a maternal depression roundtable: a US perspective. Arch Women Ment Health 2002; 4: 79–82CrossRef
36.
Barrio LM, Burt VK. Depression in pregnancy: strategies for primary care management. Women’s Health Prim Care 2000; 3: 490–8
37.
US Department of Health and Human Services, Public Health Service, and Agency for Health Care Policy and Research. Depression Guideline Panel. Depression in primary care: volume 1: detection and diagnosis. Clinical Practice Guideline, No. 5. Rockville (MD): AHCPR, 1993. Publication No. 93-0550
38.
Sharp LK, Lipsky MS. Screening for depression across the lifespan: a review of measures for use in primary care settings. Am Fam Physician 2002; 66: 1001–8PubMed
39.
Beck AT. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 53–61CrossRef
40.
Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measure 1977; 1: 385–401CrossRef
41.
Spitzer RL, Kroenke K, Willaims JB. Validation and utility of a self-report version of PRIME-MD: the PHQ Primary Care Study. JAMA 1999; 282: 1737–44PubMedCrossRef
42.
Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression: development of the Edinburgh Postnatal Depression Scale. Br J Psychiatry 1987; 150: 782–6PubMedCrossRef
43.
Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care: The PRIME-MD 1000 Study. JAMA 1994; 272: 1749–56PubMedCrossRef
44.
Murray D, Cox JL. Screening for depression during pregnancy with the Edinburgh depression scale (EPDS). J Reprod Infant Psychol 1990; 8: 99–107CrossRef
45.
Holcomb WL, Stone LS, Lustman PJ, et al. Screening for depression in pregnancy: characteristics of the Beck Depression Inventory. Obstet Gynecol 1996; 88: 1021–5PubMedCrossRef
46.
Spitzer RL, Williams JB, Kroenke K, et al. Validity and utility of the PRIME-MD patient health questionnaire in assessment of 3000 obstetric-gynecologic patients: the PRIME-MD patient health questionnaire obstetrics-gynecology study. Am J Obstet Gynecol 2000; 183: 759–69PubMedCrossRef
47.
Cox JL, Chapman G, Murray D, et al. Validation of the Edinburgh postnatal depression scale (EPDS) in non-postnatal women. J Affect Disord 1996; 39: 185–9PubMedCrossRef
48.
Salamero M, Marcos T, Gutierrez F, et al. Factorial study of the BDI in pregnant women. Psychol Med 1994; 24: 1031–5PubMedCrossRef
49.
50.
Farvolden P, Kennedy SH, Lam RW. Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future. Expert Opin Investig Drugs 2003; 12: 65–86PubMedCrossRef
51.
Nemeroff CB. Recent advances in the neurobiology of depression. Psychopharmacol Bull 2002; 36: 6–23PubMed
52.
53.
54.
Pfost KS, Stevens MJ, Lum CU. The relationship of demographic variables, antepartum depression, and stress to postpartum depression. J Clin Psychol 1990; 46: 588–92PubMedCrossRef
55.
Chrousos GP, Torpy DJ, Gold PW. Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. Ann Intern Med 1998; 129: 229–40PubMed
56.
Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: implicatons for therapy. J Affect Disord 2001; 62: 77–91PubMedCrossRef
57.
Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar depression. JAMA 1996; 276: 293–9PubMedCrossRef
58.
Eaton WW, Anthony JC, Gallo J, et al. Natural history of diagnostic Interview Schedule/DSM-IV major depression: the Baltimore Epidemiologic Catchment Area follow-up. Arch Gen Psychiatry 1997; 54: 993–9PubMedCrossRef
59.
Parikh SV, Lam RW. Clinical guidelines for the treatment of depressive disorder: 1. definitions, prevalence, and health burden. Can J Psychiatry 2001; 46: 13–20S
60.
Thornicroft G, Sartorius N. The course and outcome of depression in different cultures: 10-year follow-up of the WHO collaborative study on the assessment of depressive disorders. Psychol Med 1993; 23: 1023–32PubMedCrossRef
61.
Keller MB. Recovery in major depressive disorder: analysis with the life table and regression models. Arch Gen Psychiatry 1982; 39: 905–10PubMedCrossRef
62.
Affonso DD, Lovett S, Paul N, et al. A standardized interview that differentiates pregnancy and postpartum symptoms from perinatal clinical depression. Birth 1990; 17: 121–30PubMedCrossRef
63.
Kitamura T, Shima S, Sugawara M, et al. Psychological and social correlates of the onset of affective disorders among pregnant women. Psychol Med 1993; 23: 967–75PubMedCrossRef
64.
Pajulo M, Savonlahti E, Sourander A, et al. Antenatal depression, substance dependency and social support. J Affect Disord 2001; 65: 9–17PubMedCrossRef
65.
Kurki T, Hiilesmaa V, Raitasalo R, et al. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000; 95: 487–90PubMedCrossRef
66.
Hoffman S, Hatch MC. Depressive symptomatology during pregnancy: evidence for an association with decreased fetal growth in pregnancies of lower social class women. Health Psychol 2000; 19: 535–43PubMedCrossRef
67.
Wu J, Viguera A, Riley L, et al. Mood disturbance in pregnancy and the mode of delivery. Am J Obstet Gynecol 2002; 187: 864–7PubMedCrossRef
68.
Bolton HL, Hughes PM, Turton P, et al. Incidence and demographic correlates of depressive symptoms during pregnancy in an inner London population. J Psychosom Obstet Gynaecol 1998; 19: 202–9PubMedCrossRef
69.
Josefsson A, Berg G, Nordin C, et al. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand 2001; 80: 251–5PubMedCrossRef
70.
Marcus SM, Flynn HA, Blow FC, et al. Depressive symptoms among pregnant women screened in obstetrics settings. J Womens Health 2003; 12: 373–80CrossRef
71.
Seguin L, Potvin L, St-Denis M, et al. Chronic Stressors, social support, and depression during pregnancy. Obstet Gynecol 1995; 85: 583–9PubMedCrossRef
72.
73.
Andersson L, Sundstrom-Poromaa I, Bixo M, et al. Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. Am J Obstet Gynecol 2003; 189: 148–54PubMedCrossRef
74.
Areias ME, Kumar R, Barros H, et al. Comparative incidence of depression in women and men, during pregnancy and after childbirth. Validation of the Edinburgh Postnatal Depression Scale in Portuguese mothers. Br J Psychiatry 1996; 169: 30–5PubMedCrossRef
75.
Birndorf CA, Madden A, Portera L, et al. Psychiatric symptoms, functional impairment, and receptivity toward mental health treatment among obstetrical patients. Int J Psychiatry Med 2001; 31: 355–65PubMedCrossRef
76.
Chung TK, Lau TK, Yip AS, et al. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med 2001; 63: 830–4PubMed
77.
Da Silva VA, Moraes-Santos Ar, Carvalho MS, et al. Prenatal and postnatal depression among low income Brazilian women. Brazil J Med Biol Res 1998; 31: 799–804CrossRef
78.
Matthey S, Barnett B, Ungerer J, et al. Paternal and maternal depressed mood during the transition to parenthood. J Affect Dis 2000; 60: 75–85PubMedCrossRef
79.
O’Heron CA. Coping and postpartum depression: an analysis of coping and depression during pregnancy and the puerperium. [dissertation]. Saint Louis (MO): University of Missouri, 1991
80.
Verdoux H, Sutter AL, Glatigny-Dallay E, et al. Obstetrical complications and the development of postpartum depressive symptoms: a prospective survey of the MATQUID cohort. Acta Psychiatr Scand 2002; 106: 212–9PubMedCrossRef
81.
Zuckerman B, Amaro H, Bauchner H, et al. Depressive symptoms during pregnancy: relationship to poor health behaviours. Am J Obstet Gynecol 1989; 160: 1107–11PubMed
82.
83.
Spinelli MG. Antepartum and postpartum depression. J Gend Specif Med 1998; 1: 33–6PubMed
84.
Cefalo RC. The detection and treatment of psychiatric disorders and substance use among pregnant women cared for in obstetrics. Obstet Gynecol Surv 2002; 57: 68–9CrossRef
85.
Wisner KL, Gelenberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999; 282: 1264–9PubMedCrossRef
86.
Lundy B, Field T. Newborns of mothers with depressive symptoms are less expressive. Infant Behav Dev 1996; 19: 419–24CrossRef
87.
Lundy B, Jones NA, Field T, et al. Prenatal depression effects on neonates. Infant Behav Dev 1999; 22: 119–29CrossRef
88.
Zuckerman B, Bauchner H, Parker S, et al. Maternal depressive symptoms during pregnancy, and newborn irritability. J Dev Behav Pediatr 1990; 11: 190–4PubMedCrossRef
89.
Steer RA, Scholl TO, Hediger ML, et al. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 1992; 45: 1093–9PubMedCrossRef
90.
Simon G, VonKorff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry 1995; 52: 850–6PubMedCrossRef
91.
Bixo M, Sundstrom-Poromaa I, Bjorn I, et al. Patients with psychiatric disorders in gynecologic practice. Am J Obstet Gynecol 2001; 185: 396–402PubMedCrossRef
92.
US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, and Center for Mental Health Services. Mental health: a report of the surgeon general. Rockville (MD): NIH, NIMH, 1999
93.
Parikh SV, Wasylenki D, Goering P, et al. Mood disorders: rural/urban differences in prevalence, health care utilization, and disability in Ontario. J Affect Disord 1996; 38: 57–65PubMedCrossRef
94.
Kessler RC, Barber C, Birnbaum HG, et al. Depression in the workplace: effects on short-term disability. Health Aff 2002; 18: 163–71CrossRef
95.
Goff VV. Depression: a decade of progress, more to do. NHPF Issue Brief 2002; 786: 1–14PubMed
96.
Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders: results from the PRIME-MD Study. JAMA 1995; 274: 1511–7PubMedCrossRef
97.
Committee to Study the Prevention of Low Birthweight. Eitology and risk factors. Washington (DC): National Academy Press, 1985
98.
Kelly RH, Russo J, Holt VL, et al. Psychiatric and substance use disorders as risk factors for low birth weight and preterm delivery. Obstet Gynecol 2002; 100: 297–304PubMedCrossRef
99.
Nordentoft M, Lou HC, Hansen D, et al. Intrauterine growth retardation and premature delivery: the influence of maternal smoking and psychosocial factors. Am J Public Health 1996; 86: 347–54PubMedCrossRef
100.
Carter AS, Wood Baker C, Brownell KD. Body mass index, eating attitudes, and symptoms of depression and anxiety in pregnancy and the postpartum period. Psychosom Med 2000; 62: 264–70PubMed
101.
National High Blood Pressure Education Working Group. National High Blood Pressure Education Working Group report on high blood pressure in pregnancy. Am J Obstet Gynecol 1990; 163: 1689–712
102.
MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 2001; 97: 533–8PubMedCrossRef
103.
Paarlberg KM, Vingerhoets JJ, Passchier J, et al. Psychosocial factors and pregnancy outcome: a review with emphasis on methodological issues. J Psychosom Res 1995; 39: 563–95PubMedCrossRef
104.
Einarson A, Koren G. Bacterial vaginosis during pregnancy: should we screen for and treat it? Can Fam Physician 2002; 28: 877–88
105.
Zhang J, Klebanoff MA, Levine RJ, et al. The puzzling association between smoking and hypertension during pregnancy. Am J Obstet Gynecol 1999; 181: 1407–13PubMedCrossRef
106.
Conde-Agudelo A, Althabe F, Belizan JM, et al. Cigarette smoking during pregnancy and risk of preeclampsia: a systematic review. Am J Obstet Gynecol 1999; 181: 1026–35PubMedCrossRef
107.
Lindqvist PG, Marsal K. Moderate smoking during pregnancy is associated with a reduced risk of preeclampsia. Acta Obstet Gynecol Scand 1999; 78: 693–7PubMedCrossRef
108.
Vintzileos A, Ananth CV, Smulian CV, et al. The impact of prenatal care in the United States on preterm births in the presence and absence of antenatal high-risk conditions. Am J Obstet Gynecol 2002; 187: 1254–7PubMedCrossRef
109.
Vintzileos A, Smulian CV, Scorza WE, et al. The impact of prenatal care on postneonatal deaths in the presence and absence of antenatal high-risk conditions. Am J Obstet Gynecol 2002; 187: 1258–62PubMedCrossRef
110.
Kogan M, Alexander R, Jack B, et al. The association between adequacy of prenatal care utilization and subsequent pediatric care utilization in the United States. Pediatrics 1988; 102: 25–30CrossRef
111.
Kelly RH, Danielsen B, Golding J, et al. Adequacy of prenatal care among women with psychiatric diagnoses giving birth in California in 1994 and 1995. Psychiatr Serv 1999; 50: 1584–90PubMed
112.
Murray J, Bernfield ML. The differential effect of prenatal care on the incidence of low birth weight among blacks and white in a prepaid health care plan. N Engl J Med 1988; 319: 1385–91PubMedCrossRef
113.
National Institutes of Health. National pregnancy and health survey: drug use among women delivering livebirths. Rockville (MD): 1992. Dept of Health and Human Services, National Institute of Drug Abuse; 1996. NIH publication no. 96-3819
114.
Wisbourg K, Kesmodel U, Henriksen TB, et al. A prospective study of smoking during pregnancy and SIDS. Arch Dis Child 2000; 83: 203–6CrossRef
115.
Mathews TJ, Menacker F, MacDorman MF. Infant mortality statistics from the 2001 period linked birth/infant death data set. Natl Vital Stat Rep 2003; 52: 1–28PubMed
116.
Centers for Disease Control and Prevention. Alcohol consumption among pregnant women and childbearing-aged women: United States, 1991 and 1995. MMWR 1997; 46: 346–50
117.
Serdula M, Williamson DF, Kendrick JS, et al. Trends in alcohol consumption by pregnant women: 1985 through 1988. JAMA 1991; 265: 876–9PubMedCrossRef
118.
Ebrahmi SH, Luman ET, Floyd RL, et al. Alcohol consumption by pregnant women in the United States during 1988–1995. Obstet Gynecol 1998; 92: 187–92CrossRef
119.
Health Canada. Canadian perinatal health report, 2000. Ottawa (ON): Minister of Public Works and Government Services Canada, 2000: Cat. No. H49-142/2000E
120.
Kelly RH, Zatzick DF, Anders TF. The detection and treatment of psychiatric disorders and substance use among pregnant women cared for in obstetrics. Am J Psychiatry 2001; 158: 213–9PubMedCrossRef
121.
Horrigan TJ, Schroeder AV, Schaffer RM. The triad of substance abuse, violence, and depression are interrelated in pregnancy. J Subst Abuse 2000; 18: 55–8CrossRef
122.
Polygenis D, Wharton S, Malmberg C, et al. Moderate alcohol consumption during pregnancy and the incidence of fetal malformations: a meta-analysis. Neurotoxicol Teratol 1998; 20: 61–7PubMedCrossRef
123.
Koren G, Loebstein R, Nulman I. Fetal alcohol syndrome: role of the family physician. Can Fam Physician 1998; 44: 38–40PubMed
124.
Mattson SN, Schoenfeld AM, Riley EP. Teratogenic effects of alcohol on brain and behavior. Alcohol Res Health 2001; 25: 185–91PubMed
125.
Autti-Ramo I. Foetal alcohol syndrome: a multifaceted condition. Dev Med Child Neurol 2002; 44: 141–4PubMedCrossRef
126.
Hard ML, Einarson TR, Koren G. The role of acetaldehyde in pregnancy outcome after prenatal alcohol exposure. Ther Drug Monit 2001; 23: 427–34PubMedCrossRef
127.
Makarechian N, Agro K, Devlin J, et al. The relationship between moderate alcohol consumption during pregnancy and spontaneous abortion, stillbirth, premature birth and birth weight: a meta-analysis. Can J Clin Pharmacol 1998; 5: 169–76
128.
Kandall SR, Gaines J, Habel L, et al. Relationship of maternal substance abuse to subsequent sudden infant death syndrome in offspring. J Pediatr 1993; 23: 120–6
129.
Goldstein RB, Mcavay GJ, Nunes EV, et al. Maternal life history: versus gestation-focused assessment of prenatal exposure to substances of abuse. J Subst Abuse 2000; 11: 355–68PubMedCrossRef
130.
Lepine JP. Epidemiology, burden, and disability in depression and anxiety. J Clin Psychiatry 2001; 62: 4–10PubMed
131.
Cuijpers P, Smit F. Excess mortality in depression: a meta-analysis of community studies. J Affect Disord 2002; 72: 227–36PubMedCrossRef
132.
Weissman MM, Bland RC, Canino GJ, et al. Prevalence of suicide ideation and suicide attempts in nine countries. Psychol Med 1999; 29: 9–17PubMedCrossRef
133.
Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001; 26: 44–8PubMed
134.
Lewis G, Drife J, Botting B, Carson C, Cooper G, Hall M, McCormick C, Neilson J, Oates M, Shaw R, de Swiet M, Millward-Sadler H, Thomas T, Thompson W, Willats S. Why mothers die 1997–1999: the fifth report of the confidential enquiries into maternal deaths in the United Kingdom. London, UK: Royal College of Obstetricians and Gynaecologists Press, 2001
135.
Marzuk PM, Tardiff K, Leon AC, et al. Lower risk of suicide during pregnancy. Am J Psychiatry 1997; 154: 122–3PubMed
136.
Orr ST, James SA, Blackmore Prince C. Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. Am J Epidemiol 2002; 156: 797–802PubMedCrossRef
137.
Perkin MR, Bland JM, Peacock JL, et al. The effect of anxiety and depression during pregnancy on obstetric complications. Br J Obstet Gynaecol 1993; 100: 629–34PubMedCrossRef
138.
Stowe ZN, Nemeroff CB. Women at risk for postpartum-onset major depression. Am J Obstet Gynecol 1995; 173: 639–45PubMedCrossRef
139.
Chaudron LH, Klein MH, Remington P, et al. Predictors, prodromes and incidence of postpartum depression. J Psychosom Obstet Gynaecol 2001; 22: 103–12PubMedCrossRef
140.
Beck CT. Revision of the postpartum depression predictors inventory. J Obstet Gynecol Neonatal Nurs 2001; 31: 394–402
141.
142.
O’Hara MW, Swain AM. Rates and risk of postpartum depression: a meta-analysis. Int Rev Psychiatry 1996; 8: 37–54CrossRef
143.
144.
Beck CT. Theoretical perspectives of postpartum depression and their treatment implications. MCN Am J Matern Child Nurs 2002; 27: 282–7PubMedCrossRef
145.
146.
Allister L, Lester BM, Carr S, et al. The effects of maternal depression on fetal heart rate response to vibroacoustic stimulation. Dev Neuropsychol 2001; 20: 639–51PubMed
147.
Monk C. Stress and mood disorders during pregnancy: implications for child development. Psychiatr Q 2001; 72: 347–57PubMedCrossRef
148.
Glover V, O’Connor TG. Effects of antenatal stress and anxiety: implications for development and psychiatry. Br J Psychiatry 2002; 180: 389–91PubMedCrossRef
149.
Hendrick V, Altshuler L. Management of major depression during pregnancy. Am J Psychiatry 2002; 159: 1667–73PubMedCrossRef
150.
Coverdale JH, Chervenak FA, Bayer T, et al. Ethically justified clinically comprehensive guidelines for the management of the depressed pregnant patient. Am J Obstet Gynecol 1996; 174: 169–73PubMedCrossRef
151.
Buist A. Managing depression in pregnancy. Aust Fam Physician 2000; 29: 663–7PubMed
152.
Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142: 402–8PubMedCrossRef
153.
Compendium of Pharmaceuticals and specialties 2002. Ottawa (ON): Canadian Pharmacists Association, 2002
154.
Better news on population [noticeboard]. Lancet 2003; 339: 1600
155.
Einarson A, Portnoi G, Koren G. Update on Motherisk updates. Can Fam Physician 2002; 48: 1301–4PubMed
156.
Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010–5PubMedCrossRef
157.
Cohen LS, Heller VL, Bailey JW, et al. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000; 48: 996–1000PubMedCrossRef
158.
Ericson A, Kallen B, Wilholm BE. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Pharmacol 1999; 55: 503–8CrossRef
159.
Kulin N, Pastuszak A, Sage S, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA 1998; 279: 609–10PubMedCrossRef
160.
Mc Connell Linn Filkins. Depression and pregnancy: use of selective serotonin reuptake inhibitors in pregnancy. Prim Care Update Ob Gyns 1998; 5: 11–5CrossRef
161.
Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003; 188: 812–5PubMedCrossRef
162.
McElhatton PR, Garbis HM, Elefant E, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants: a collaborative study of the European network of Teratology Information Services (ENTIS). Reprod Toxicol 1996; 10: 285–94PubMedCrossRef
163.
Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med 2000; 30: 89–94PubMedCrossRef
164.
Misri S, Burgmann A, Kostaras D. Are SSRIs safe for pregnant and breastfeeding women? Can Fam Physician 2000; 46: 626–8PubMed
165.
Austin MP, Mitchell PB. Psychotropic medications in pregnant women: treatment dilemmas. Med J Aust 1998; 169: 428–31PubMed
166.
Altshuler LL, Cohen LS, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153: 592–606PubMed
167.
Nulman I, Rovet J, Stewart D, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336: 258–62PubMedCrossRef
168.
Nulman I, Rovet J, Stewart D, etal. Child development following exposure to tricyclic antidepresants or fluoxetine throughout fetal life: a prospective controlled study. Am J Psychiatry 2002; 159: 1889–95PubMedCrossRef
169.
Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159: 2055–61PubMedCrossRef
170.
Mattson S, Eastvold A, Jones K, Harris J, Chambers C. Neurobehavioral follow-up of children prenatally exposed to fluoxetine [abstract]. Teratology 1999; 59: 376
171.
Nordeng H, Lindemann R, Perminov KV, et al. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001; 90: 288–91PubMedCrossRef
172.
Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002; 156: 1129–32PubMedCrossRef
173.
Oberlander TF, Grunau RE, Fitzgerald C, et al. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 2002; 51: 443–53PubMedCrossRef
174.
Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 369: 2246–8CrossRef
175.
176.
Doskoch P. Which is more toxic to a fetus: antidepressants or maternal depression [letter]? Neuropsychiatry Rev 2001; 2: 1
177.
Thorpe L, Whitney DK, Kutcher SP, et al. Clinical guidelines for the treatment of depressive disorders: VI. Special populations. Can J Psychiatry 2001; 46: 647–768
178.
Spinelli MG, Endicott J. Controlled clinical trial of interpersonal psychotherapy versus parenting education program for depressed pregnant women. Am J Psychiatry 2003; 160: 555–62PubMedCrossRef
179.
Tylee A. Depression in Europe: experience from the DEPRES II survey. Eur Neuropsychopharmacol 2000; 10: S445–8PubMedCrossRef
180.
181.
Hirschfeld R, Keller M, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997; 277: 333–40PubMedCrossRef
182.
Abraham S. Obstetricians and maternal body weight and eating disorders during pregnancy. J Psychosom Obstet Gynaecol 2001; 22: 159–63PubMedCrossRef
183.
Lyszkiewicz DA, Gerichhausen S, Bjornsdottir I, et al. Evidence based information on drug use during pregnancy: a survey of community pharmacists in three countries. Pharm World Sci 2001; 23: 76–81PubMedCrossRef
184.
Jasper JD, Goel R, Einarson A, et al. Effects of framing on teratogenic risk perception in pregnant women. Lancet 2001; 358: 1237–8PubMedCrossRef
185.
Schmidt LA, Greenberg BD, Holzman GB, et al. Treatment of depression by obstetrician-gynecologists: a survey study. Obstet Gynecol 1997; 90: 296–300PubMedCrossRef
186.
Altshuler LL, Cohen LS, Moline ML, et al. The expert consensus guideline series: treatment of depression in women. Postgrad Med 2001; 1: 1–107
187.
Austin MP. Psychosocial assessment and management of depression and anxiety in pregnancy. Aust Fam Physician 2003; 32: 119–26PubMed
188.
Williams JW, Hitchcock Noel P, Cordes JA, et al. Is this patient clinically depressed? JAMA 2002; 287: 1160–70PubMedCrossRef
189.
Altshuler LL, Hendrick V, Cohen LS. Course of mood and anxiety disorders during pregnancy and the postpartum period. J Clin Psychiatry 1998; 59: 29–33PubMed
190.
Dawes M, Chowienczyk PJ. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol 2001; 15: 819–26PubMedCrossRef
191.
Hostetter A, Stowe ZN, Strader JR, et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 2000; 11: 51–7PubMedCrossRef
192.
Altshuler LL, Hendrick VC. Pregnancy and psychotropic medication: changes in blood levels. J Clin Psychopharmacol 1996; 16: 78–80PubMedCrossRef
193.
Wisner KL, Perel JM, Wheeler SB. Tricyclic dosage requirements across pregnancy. Am J Psychiatry 1993; 150: 1541–2PubMed
194.
Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002; 72: 184–91PubMedCrossRef
195.
Einarson A, Miropolsky V, Varma B, et al. Determinants of physicians’ decision-making regarding the prescribing of antidepressant medication during pregnancy [abstract]. Fifteenth International Conference of the Organization of Teratology Information Services (OTIS); 2002 Jun 22–25; Arizona. Teratology 2002; 65: 369–70
196.
Einarson A, Selby P, Koren G. Discontinuing antidepressants and benzodiazepines upon becoming pregnant. Can Fam Physician 2001; 47: 457–672
Metadata
Title
Depression during Pregnancy
Overview of Clinical Factors
Authors
Ms Heather A. Bennett
Adrienne Einarson
Anna Taddio
Gideon Koren
Thomas R. Einarson
Publication date
01-03-2004
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 3/2004
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200424030-00004

Other articles of this Issue 3/2004

Clinical Drug Investigation 3/2004 Go to the issue

Original Research Article

Cotrimoxazole in the Treatment of Acute Uncomplicated Falciparum Malaria in Nigerian Children

Original Research Article

Efficacy and Safety of the Platelet-Activating Factor Receptor Antagonist BN 52021 (Ginkgolide B) in Patients with Severe Sepsis

Case Report

Pancreotoxicity of Propofol Sedation during Purulent Meningitis

Original Research Article

Pharmacokinetics, Preliminary Efficacy and Safety of Subcutaneous Melagatran and Oral Ximelagatran